Introduction
Cardiopulmonary bypass (CPB) induces inflammation associated with hemodilution, ischemiayreperfusion, and other effects w1x. The inflammatory reaction is typically transient, but severely damaging effects are possible due to complement activation, pro-inflammatory cytokines, neutrophil stimulation, and endothelial activation w1x. Post-CPB inflammation is especially pronounced in the lungs w2x, leading to pulmonary edema and pulmonary hypertension (pHTN), both significant components of cardiopulmonary dysfunction seen after CPB w3x. Increased concentrations of various inflammatory mediators within pulmonary secretions have been noted after CPB and other injury models and are correlated with adverse clinical outcomes w4, 5x.
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૾૾ The views expressed represent those of the authors and do not represent Modified ultrafiltration (MUF) was introduced in neonates and children undergoing cardiac surgery with CPB in order to reduce postoperative edema w6x. In a prospective, randomized trial, MUF reduced total body water accumulation and the need for postoperative blood transfusions w6x. In addition, MUF has been associated with reduced morbidity following CPB w3x. However, the specific mechanisms by which MUF exerts positive clinical benefits remain incompletely defined. Based on previous studies, we hypothesized that CPB induces the expression of inflammatory mediators within the lungs. Furthermore, we expected inflammatory mediators to be affected by MUF, which would help explain observed clinical benefits.
Materials and methods
Twenty-four neonatal piglets (mean weight 8.4"0.4 kg) were randomized in two equal groups, controls (ns12) and MUF (ns12) prior to experimentation. All animals received humane care in compliance with the 'Principles of Laboratory Animal Care' (National Society for Medical Research) and the Guide for the Care and Use of Laboratory Animals (NIH publication No. 86-23, revised 1996) .
Anesthesia and surgical preparation
Each subject was sedated wketamine (15 mgykg, i.m.) and atropine (0.02-0.05 mgykg, i.m.)x before orotracheal intubation. Fentanyl (30-200 mgykgyh i.v.) and ketamine (4-10 mgyh i.v.) infusions maintained anesthesia throughout the study. Subjects were paralyzed (pancuronium, 0.7 mgykg i.v. bolus and 0.1 mgykgyh i.v. infusion). After median sternotomy and pericardiotomy, pressure transducer catheters were placed in the right atrium (RA), left atrium (LA), and pulmonary artery (PA). A 10-mm flow probe (Transonics System, Inc, Ithaca, NY, USA) encircled the aorta proximal to the innominate artery, allowing cardiac output (CO) determination. After recording baseline measurements, the RA and innominate artery were cannulated for CPB.
Conduct of cardiopulmonary bypass
The CPB circuit was primed with crystalloid solution and fresh donor porcine whole blood, maintaining a circuit hematocrit (HCT) percentage of 18-22%. Each subject was anticoagulated (unfractionated heparin, 300 Uykg) and placed on hypothermic (28 8C) CPB at calculated flows of 120 mlykgymin. The aorta was not clamped. After 60 min of CPB, subjects were rewarmed to 36 8C and weaned from CPB. During rewarming, neither group underwent ultrafiltration.
Technique of modified ultrafiltration
A size-appropriate, polyarylethersulfone hemoconcentrator (COBE HC 700 Midi COBE Cardiovascular Arvada, CO, USA) was placed between the arterial and venous limbs of the CPB circuit. The hemoconcentrator inlet was clamped during CPB. After CPB, the inlet was unclamped, permitting perfusion from the arterial CPB limb through the filter (10-15 mlykgymin) before returning to the subject via the venous limb. Additional blood from the venous reservoir was returned to the venous cannula as needed to maintain intravascular volume and stable hemodynamics. Inotropic support after separating from CPB was avoided. Arteriovenous MUF was performed until the HCT reached the goal of 35%.
Hemodynamic data collection
CO was estimated by integrating aortic flow probe data over 15 s. Mean pulmonary artery (MP ) pressures and left PA atrial (MP ) pressures were recorded directly. Pulmonary LA vascular resistance (PVR) was determined as:
( 1) PA LA
Inflammatory cytokine assessment
At each study time point, 10 ml of sterile saline was injected via the endotracheal tube, followed by gentle suctioning to retrieve bronchoalveolar lavage (BAL) specimens for alveolar cytokines IL-6, IL-8, and tumor necrosis factor (TNF)-a. Systemic venous blood was collected at each study time point for determination of IL-6, IL-8, and TNF-a concentrations. Ten milliliter aliquots of MUF were collected to quantify the presence of pro-inflammatory cytokines. The concentration of each cytokine was determined using enzyme-linked immunosorbent assays (ELISA, R&D Systems, Minneapolis, MN, USA). Samples were stored at -90 8C and batch processed.
Transpulmonary thromboxane gradient
Serum samples for transpulmonary TxB2 gradients were taken from the PA and left atrium immediately prior to instituting CPB, immediately prior to separating from CPB, and at the end of study (EOS). TxB2 concentrations were determined using ELISA (Cayman Chemical, Ann Arbor, MI, USA), with samples diluted 1:10 as per the manufacturer's instructions.
Study endpoint
Following separation from CPB (control group) or completion of MUF, subjects were euthanized 4 hours later (EOS). Physiological data were recorded prior to EOS. Euthanasia was performed by intravenous overdose of sodium pentobarbital (Euthanasia-5 solution , 100 mgykg). 
Data analysis
Student's t-tests compared data between groups at various study time points, while analysis of variance (ANOVA) with repeated measures compared data within individual groups at different study time points. A P-0.05 was considered significant. Analyses were carried out using Intercooled STATA Version 9.0 software (College Station, TX, USA). All data are reported as mean"standard deviation unless otherwise noted.
Results
Baseline weights and baseline and postCPB %HCT were similar between groups. After MUF, %HCT was significantly increased (postCPB HCT 21.7"3.3% vs. postMUF HCT 33.6"2.3%, P-0.001). Mean arterial pressure (MAP) was similar between groups at all study time points (Table 1) , but postMUF MAP was significantly increased relative to the postCPB state in MUF subjects (postCPB MAP 40.2" 6.4 mmHg vs. postMUF MAP 51.7"11 mmHg, Ps0.005). Following CPB, PVR was significantly increased in both groups. PVR increased among controls to EOS, but MUF was associated with significantly reduced PVR relative to postCPB data, and was significantly less at EOS compared with controls (MUF PVR 5500"1900 dynesysycm vs. control 5 PVR 10,100"5100 dynesysycm ; Ps0.03; Fig. 1 ).
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Plasma concentrations of proinflammatory cytokines were evaluated at baseline, after CPB, and EOS in both groups. In both groups, TNF-a concentrations postCPB were significantly elevated compared with baseline ( Table 2) . Subsequently, TNF-a plasma concentrations did not change in either group. IL-6 and IL-8 concentrations were unchanged postCPB relative to baseline in both groups. However, IL-6 and IL-8 concentrations were significantly elevated at EOS relative to baseline in both groups; no differences between Downloaded from https://academic.oup.com/icvts/article-abstract/11/5/599/656354 by guest on 21 January 2019 Control 1040"1600 7200"8600 10,000"5500 MUF 1700"900 8600"3000 5500"1900 EOS, end of study. Fig. 1 . Pulmonary vascular resistance (PVR) significantly increased in both control and MUF groups after CPB. PVR significantly decreased after MUF but continued to increase during monitored recovery in the control group. MUF, modified ultrafiltration; CPB, cardiopulmonary bypass; EOS, end of study. MUF and control were observed ( Table 2) . Examination of the ultrafiltrate collected during MUF was notable for significant concentrations of proinflammatory cytokines, indicating successful removal of each of these inflammatory mediators during MUF ( Table 2) . Alveolar TNF-a concentrations were not different between groups or within groups at any time point (Fig. 2) . Conversely, alveolar IL-8 concentrations increased in both groups following CPB relative to baseline. In addition, BAL IL-8 concentration was significantly higher at EOS in controls compared with the postCPB time point (Ps0.036), while BAL IL-8 did not increase further after MUF (Fig. 3) . Similarly, CPB increased alveolar IL-6 concentrations in both groups relative to baseline (Fig. 4) . BAL IL-6 was significantly increased in controls at EOS compared with postCPB (Fig.  4, Ps0.01 ). In contrast, BAL IL-6 did not increase after MUF and at EOS BAL IL-6 concentration was significantly less among MUF subjects compared with control subjects (Fig. 4, Ps0.015) .
The transpulmonary TxB2 gradient was determined at baseline, after CPB, and at EOS in both groups. In the MUF group, transpulmonary TxB2 gradient was significantly reduced at EOS compared with the postCPB state w208"200 pgyml postCPB vs. 141"120 pgyml EOS, Ps0.04; (Fig. 5) x. In contrast, transpulmonary TxB2 gradient was significantly increased in controls at EOS relative to postCPB state w63"60 pgyml postCPB vs. 730"360 pgyml EOS, Ps0.04; (Fig. 5) x. The difference in TxB2 gradients between MUF subjects and controls at EOS was also significant (Ps0.04).
Discussion
This study assessed the pulmonary inflammatory response to CPB and its potential attenuation with MUF in a neonatal piglet model. Following CPB, subjects undergoing MUF demonstrated significantly reduced pulmonary-based inflammation, as reflected by reduced pHTN, reduced alveolar concentrations of IL-6 and IL-8 relative to controls, and decreased transpulmonary TXB2 concentrations. These observations are among the most informative details describing the physiological effects of MUF and lend insight into the possible mechanisms behind the well-recognized clinical benefits of MUF w3, 6x. These results suggest that MUF exerts beneficial postCPB effects by mitigating the consequences of upregulated mediators of inflammation, reducing effective pulmonary concentrations of inflammatory cytokines, and limiting the cascade of inflammatory events leading to adverse clinical outcomes. Fig. 2 . Data for bronchoalveolar lavage (BAL) concentrations of TNF-a in pgyml are shown for control (white bars) and MUF (black bars) at time points baseline, postCPB, and end of study. A modest but statistically insignificant increase in TNF-a concentration postCPB relative to baseline conditions was seen in both groups. At end of study, BAL concentrations of TNF-a were unchanged relative to the postCPB state in both groups. MUF, modified ultrafiltration; CPB, cardiopulmonary bypass. Fig. 4 . Data for bronchoalveolar lavage (BAL) concentrations of IL-6 in pgyml are shown for control (white bars) and MUF (black bars) at baseline, postCPB, and end of study. BAL concentrations of IL-6 were insignificantly increased after CPB relative to baseline. At end of study, IL-6 concentrations were significantly increased for controls relative to the postCPB state, indicating on-going inflammatory response (Ps0.01). In contrast, MUF was associated with significantly reduced IL-6 concentrations at end of study compared with controls relative to the postCPB state (Ps0.015). CPB, cardiopulmonary bypass; MUF, modified ultrafiltration. Fig. 3 . Data for bronchoalveolar lavage (BAL) concentrations of IL-8 in pgyml are shown for control (white bars) and MUF (black bars) at baseline, post-CPB, and end of study. BAL concentrations of IL-8 were insignificantly increased after CPB relative to the baseline. At end of study, IL-8 concentrations were significantly increased for controls relative to the postCPB state, indicating on-going inflammatory response (Ps0.036). This affect appears blunted by MUF, since BAL IL-8 concentrations at end of study were unchanged relative to the postCPB state. CPB, cardiopulmonary bypass; MUF, modified ultrafiltration. The proinflammatory cytokines evaluated in this study are notorious in CPB-induced inflammation. Following institution of CPB, various systemic inflammatory mediators are released and activate circulating neutrophils. In turn, neutrophils stimulate locally-active proinflammatory cytokines in tissues, such as the lung to propagate the inflammatory response w1x. For example, cytokines released within the pulmonary alveoli may diffuse into the pulmonary interstitium to 'prime' the pulmonary endothelium for neutrophil adherence and inflict further tissue damage w7x. These processes most likely underlie heightened inflammatory responses within the lung w2, 6, 7x.
It is interesting to note that plasma TNF-a concentrations peaked earliest after CPB in the present study (Table 1) , and TNF-a appeared in greatest concentrations within the ultrafiltrate. Since TNF-a is recognized as the chief proinflammatory cytokine activating neutrophils early in the inflammatory response w8x, it one potential mechanism to explain reduced inflammation in the present study (reduced alveolar IL-6 and IL-8 concentrations) could be reduced TNF-a -neutrophil interactions after MUF, but confirmatory studies are required.
An intervention which reduces concentrations of alveolar cytokines may have direct clinical relevance since elevated alveolar levels of IL-8 and IL-6 are prognostic markers for adverse clinical outcomes associated with pulmonary inflammatory disorders w4, 5x through neutrophil activation and interference with neutrophil apoptosis, the primary method for resolving neutrophil-mediated inflammation w9x. In addition, IL-8 is a strong chemoattractant factor, leading Downloaded from https://academic.oup.com/icvts/article-abstract/11/5/599/656354 by guest on 21 January 2019 to transmigration of neutrophils from the bloodstream and into tissues, especially in the lung w10x. This phenomenon has been noted after CPB w1x. No study has directly evaluated the effect of MUF on pulmonary neutrophil activity or pulmonary neutrophil elastase concentrations, but these appear to affect pulmonary outcomes in other injury models w5x.
The observations of the present study regarding transpulmonary TxB2 concentrations corroborate TxB2 as a key mediator in postCPB pHTN w11x. Once again, activated neutrophil-endothelial interactions stimulate the release of various cytokines-induce thromboxane elaboration w11x. Therefore, preventing neutrophil adherence to vascular endothelium may blunt postCPB inflammation via reduced thromboxane production. In fact, Friedman et al. noted that neutrophil integrin blockade reduced thromboxane synthesis in sheep, resulting in less pulmonary injury after CPB w12x. Further studies are required to help define these potential mechanisms by which MUF may be involved with reduced thromboxane elaboration.
This study has several limitations. For example, we noted significant biological variability in the raw data and in several outcome variables (see Figs. 1 and 5 ). In addition, the study time points did not exactly match for the two groups studied secondary to the time required to perform MUF. However, this was typically limited to 15-30 minutes. Some of the recognized benefits of ultrafiltration may be realized regardless of the particular strategy for volume removal w13x. Therefore, we cannot specifically attribute the observed benefits to the version of ultrafiltration used in the present study. In fact, ultrafiltration performed prior to or during CPB may actually be more effective than MUF for removing inflammatory mediators w13, 14x. We studied MUF since it appears to be more uniformly applied in current clinical practice w15x.
In summary, we evaluated the effects of CPB and MUF on pulmonary-derived inflammatory mediators. For the first time, MUF is correlated with reduced alveolar concentrations of proinflammatory cytokines IL-6 and IL-8, and transpulmonary thromboxane concentrations, implying that pulmonary-based inflammation is reduced. These results lend insight into possible mechanisms by which beneficial clinical effects have been noted. However, due to the complex nature of the systems involved, additional studies are required to further characterize the biological effects by which MUF confers recognized clinical advantages.
